aibio
Financings ·
Vir Biotechnology agrees to sell Gilead 1,765,486 shares for about $25 million
The stock purchase comes with a collaboration to engineer three T-cell engager candidates for solid tumors. Closing is subject to customary conditions.
VIR Vir Biotechnology, Inc.
Vir Biotechnology (VIR) news VIR offering news
Latest Vir Biotechnology news
- Financings
Vir Biotechnology to receive $335 million from Astellas in VIR-5500 licensing deal
Vir Biotechnology agreed to co-develop VIR-5500 with Astellas for $335 million in upfront and near-term payments, plus up to $1.37 billion in later milestones. The drug is still in Phase 1, and the deal closes only after Hart-Scott-Rodino clearance.
- Financings
Vir Biotechnology signs $335 million Astellas deal, then prices stock offering at $8.50
Vir Biotechnology will receive $335 million in upfront and near-term payments from Astellas for VIR-5500, a prostate cancer T-cell engager still in Phase 1. Its February 25 prospectus supplement priced a $150,000,002 stock offering at $8.50 per share.
What Vir Biotechnology does
Vir Biotechnology is developing investigational therapies for hepatitis delta virus (HDV) and multiple solid tumors. In hepatitis delta, it has initiated its registrational ECLIPSE clinical program evaluating a combination of tobevibart and elebsiran in people living with chronic hepatitis delta. In oncology, the company is advancing three Phase 1 clinical studies of dual-masked T-cell engagers, including VIR-5500 in patients with PSMA-expressing metastatic castration-resistant prostate cancer. It is also advancing multiple undisclosed PRO-XTEN dual-masked T-cell engagers that target clinically validated targets across a variety of solid tumors. Its discovery engine combines the dAIsY platform, which uses artificial intelligence and machine learning for antibody optimization, with PRO-XTEN masking technology. Vir in-licensed PRO-XTEN from Sanofi for worldwide rights in oncology and infectious diseases. The PRO-XTEN trademark belongs to Amunix Pharmaceuticals, Inc., a Sanofi company.
| Product or program | What it is | Stage |
|---|---|---|
| Tobevibart and elebsiran | Combination for chronic hepatitis delta, ECLIPSE program | Registrational |
| VIR-5500 | Dual-masked T-cell engager for PSMA-expressing metastatic castration-resistant prostate cancer | Phase 1 |
Vir Biotechnology annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $68.6 million | $74.2 million |
| Research and development | $456.0 million | $506.5 million |
| Net income (loss) | -$438.0 million | -$522.0 million |
| Cash from operations | -$391.8 million | -$446.4 million |
| Cash and equivalents | $232.2 million | $222.9 million |
| Short-term investments | $228.8 million | $678.1 million |
Questions about Vir Biotechnology
Has Vir Biotechnology raised money recently?
Our latest story on this, dated Feb 23, 2026: "Vir Biotechnology signs $335 million Astellas deal, then prices stock offering at $8.50". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Vir Biotechnology?
Vir Biotechnology, Inc. trades under the ticker VIR on NASDAQ.
Where is Vir Biotechnology listed?
Vir Biotechnology, Inc. is listed on NASDAQ.
What is the SEC CIK of Vir Biotechnology?
The SEC Central Index Key (CIK) for Vir Biotechnology, Inc. is 1706431. Its filings are on SEC EDGAR.
How many shares does Vir Biotechnology have outstanding?
169,215,958 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Vir Biotechnology listed under?
Our directory records Vir Biotechnology, Inc. under United States.
What does Vir Biotechnology do?
Our directory classifies Vir Biotechnology, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Vir Biotechnology?
The ISIN recorded for Vir Biotechnology, Inc. is US92764N1028.
Does aibio.space cover Vir Biotechnology?
aibio.space lists Vir Biotechnology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Vir Biotechnology incorporated?
SEC records list its state or country of incorporation as DE.
What does Vir Biotechnology develop?
Vir Biotechnology is developing investigational therapies for hepatitis delta virus (HDV) and multiple solid tumors. In hepatitis delta, it has initiated its registrational ECLIPSE clinical program evaluating a combination of tobevibart and elebsiran in people living with chronic hepatitis delta.
What is Tobevibart and elebsiran from Vir Biotechnology?
Tobevibart and elebsiran: Combination for chronic hepatitis delta, ECLIPSE program Stage: Registrational.
What is VIR-5500 from Vir Biotechnology?
VIR-5500: Dual-masked T-cell engager for PSMA-expressing metastatic castration-resistant prostate cancer Stage: Phase 1.
What was Vir Biotechnology's revenue last year?
$68.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Vir Biotechnology profitable?
Vir Biotechnology, Inc. reported a net loss of $438.0 million for the fiscal year ended Dec 31, 2025, and used $391.8 million of cash in operations, per its annual report to the SEC.
Investor discussion: Vir Biotechnology
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Vir Biotechnology, Inc.
- CIK
- 1706431
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- VIR (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 1800 OWENS STREET, SAN FRANCISCO, CA, 94158
- Phone
- 415-906-4324
- Shares outstanding
- 169,215,958 as of 2026-07-29 (10-Q filed 2026-08-05)
Recent filings
Listing details
- Company
- Vir Biotechnology, Inc.
- Ticker
- VIR
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US92764N1028
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction